Microbial compositions for improving the efficacy of anticancer treatments based on immune checkpoint inhibitors and/or tyrosine kinase inhibitors and markers of responsiveness to such treatments
The invention pertains to the use of bacteria selected amongst Alistipes senegalensis, Dorea longicatena and Eubacterium siraeum for inducing immunostimulation in a patient in combination with an anti-cancer immunotherapy with an immune check-point inhibitor (ICI) and/or a tyrosine kinase inhibitor (TKI). The invention also relates to methods for assessing the probability that N a patient respond to a treatment with an ICI and/or a TKI, based on measuring the relative abundances of immunotolerant bacterial species ( Clostridium hathewayi, Clostridium clostridioforme and Clostridium boltae ) and/or immunostimulatory bacterial species CN ( Akkermansia muciniphila, Bacteroides salyersiae, Alistipes senegalensis, Dorea longicatena and Eubacterium siraeum ) in the patient's gut microbiota.
1 . A method for treating a patient with a renal cell cancer comprising administering a composition enriched for bacteria selected from the group consisting of Dorea longicatena and Eubacterium siraeum in combination with an immune checkpoint inhibitor (ICI)-based therapy or a tyrosine kinase inhibitor (TKI)-based therapy, wherein said bacterial administration results in a relative abundance of >0.855% for D. longicatena or generates a relative abundance of >1.11% for E. siraeum in a feces sample from the patient and induces immunostimulation in the cancer patient and improves efficacy of the (ICI)-based or (TKI)-based therapy.
2 . The method of claim 1 , comprising administering Dorea longicatena bacteria.
3 . The method of claim 1 , comprising administering Eubacterium siraeum bacteria.
4 . The method of claim 1 , comprising administering Dorea longicatena bacteria and Eubacterium siraeum bacteria.
5 . The method of claim 2 , further comprising administering Alistipes senegalensis bacteria.
6 . The method of claim 3 , further comprising administering Alistipes senegalensis bacteria.
7 . The method of claim 4 , further comprising administering Alistipes senegalensis bacteria.
8 . The method of claim 1 , further comprising administering bacteria of at least one species selected from the group consisting of Enterococcus hirae, Akkermansia muciniphila and Bacteroides salyersiae.
9 . The method of claim 1 , wherein said bacteria are administered in a fecal microbial composition.
10 . The method of claim 1 , wherein the bacteria are administered in combination with an ICI-based therapy.
11 . The method of claim 1 , wherein the bacteria are administered in combination with a TKI-based therapy.
12 . The method of claim 1 , wherein the bacteria are administered in combination with an ICI-based therapy and a TKI-based therapy.
13 . The method of claim 1 , further comprising the following steps prior to administering the bacteria:
(i) determining relative abundance of at least two immunotolerant species selected from the group consisting of Clostridium hathewayi, Clostridium clostridioforme and Clostridium bolteae in a biological sample from said patient;
(ii) determining relative abundance of at least two immunostimulatory species selected from the group consisting of Akkermansia muciniphila, Bacteroides salyersiae, Alistipes senegalensis, Dorea longicatena, Eubacterium siraeum in the biological sample; and
(iii) calculating the ratio of the relative abundance of the immunotolerant species of step (i) to the relative abundance of the immunostimulatory species of step (ii).
14 . The method of claim 13 , comprising determining the relative abundance of at least two immunostimulatory species selected from the group consisting of Alistipes senegalensis, Dorea longicatena , and Eubacterium siraeum.
15 . The method of claim 10 , wherein the ICI-based therapy is an anti-CTLA-4 and/or anti-PD-1 antibody therapy.
16 . The method of claim 11 , wherein the TKI-based therapy is a sunitinib, axitinib, and/or cabozantinib therapy.